Piramal Critical Care (PCC), a global leader in critical care medicines have acquired the EU, UK, Norway and South Africa commercialization rights and will sell market and distribute Neoatricon® in these countries.
About BrePco Biopharma Limited: Ireland-based BPCO develops products for the unique needs of paediatric patients. The development of Neoatricon® was part funded by the European Commission within the 7th Framework Programme (“FP7”). www.bcopharma.com
About Piramal Critical Care: Piramal Critical Care (PCC), a division of Piramal Pharma Limited, is a global leader in anaesthesia, pain management, intrathecal therapy, and critical care medicine. PCC products are available in more than 100 countries, including the US and the European markets. Piramal Critical Care has a focus on improving outcomes for patients with high quality products manufactured in-house or in partnership with leading pharmaceutical development and manufacturing organizations around the world.
For more information and updates, please visit: www.piramalcriticalcare.com
For Media enquiries:
Gillian Wright
T: +44 7454735346
E: gillian@tremplinmarketing.com
W: www.tremplinmarketing.com